158 related articles for article (PubMed ID: 25499290)
1. US hospitals object to changes in Genentech drug distribution.
Furlow B
Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
[No Abstract] [Full Text] [Related]
2. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
3. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
4. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
5. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
Zafar SY; Peppercorn JM
J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
[No Abstract] [Full Text] [Related]
6. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
7. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Kantarjian H; Mathisen MS; Lipton JH
JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
[No Abstract] [Full Text] [Related]
8. [Cost/benefit analysis of cancer drugs].
Jordan B
Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
[TBL] [Abstract][Full Text] [Related]
9. Genentech caps cost of cancer drug for some patients.
Pollack A
N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
[No Abstract] [Full Text] [Related]
10. Seeking value as cancer drug costs soar.
Bender E
Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
[TBL] [Abstract][Full Text] [Related]
11. Cancer drugs in the United States: Justum Pretium--the just price.
Kantarjian HM; Fojo T; Mathisen M; Zwelling LA
J Clin Oncol; 2013 Oct; 31(28):3600-4. PubMed ID: 23650428
[No Abstract] [Full Text] [Related]
12. Cost to the NHS of Roche oncology treatments.
Atkins M
J R Soc Med; 2007 Jul; 100(7):303. PubMed ID: 17606744
[No Abstract] [Full Text] [Related]
13. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
14. Obstacles to affordable cancer treatments.
Dusetzina SB; Muluneh B; Khan T; Richards KL; Keating NL
N C Med J; 2014; 75(4):257-60. PubMed ID: 25046090
[TBL] [Abstract][Full Text] [Related]
15. 'Financial toxicity' looms as cancer combinations proliferate.
Morrison C
Nat Biotechnol; 2015 Aug; 33(8):783-4. PubMed ID: 26252117
[No Abstract] [Full Text] [Related]
16. Obtaining financial support for patients receiving off-label drugs.
Clancey JK; Card IC
Oncol Nurs Forum; 2000 Jun; 27(5):769-70. PubMed ID: 10868389
[No Abstract] [Full Text] [Related]
17. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
American Society of Clinical Oncology
J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
[No Abstract] [Full Text] [Related]
18. Drug assistance programs for the cancer patient.
Mowad LZ; Richter SS
Cancer Pract; 2000; 8(1):49-50. PubMed ID: 10732540
[No Abstract] [Full Text] [Related]
19. Cost to the NHS of Roche oncology treatments.
Sikora K
J R Soc Med; 2007 Sep; 100(9):396-7. PubMed ID: 17766899
[No Abstract] [Full Text] [Related]
20. Oral/infusion cancer drug parity begins to raise health plan costs.
Carroll J
Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
